StocksFundsScreenerSectorsWatchlists
ACOR

ACOR - Acorda Therapeutics Inc Stock Price, Fair Value and News

0.44USD-0.22 (-33.33%)Market Closed

Market Summary

ACOR
USD0.44-0.22
Market Closed
-33.33%

ACOR Stock Price

View Fullscreen

ACOR RSI Chart

ACOR Valuation

Market Cap

819.8K

Price/Earnings (Trailing)

0

Price/Sales (Trailing)

0.01

EV/EBITDA

0.13

Price/Free Cashflow

-0.06

ACOR Price/Sales (Trailing)

ACOR Profitability

EBT Margin

-251.65%

Return on Equity

-160.08%

Return on Assets

-232.99%

Free Cashflow Yield

-1.7K%

ACOR Fundamentals

ACOR Revenue

Revenue (TTM)

117.6M

Rev. Growth (Yr)

20.7%

Rev. Growth (Qtr)

37.06%

ACOR Earnings

Earnings (TTM)

-252.9M

Earnings Growth (Yr)

-1.2K%

Earnings Growth (Qtr)

-2.4K%

Breaking Down ACOR Revenue

Last 7 days

-89.8%

Last 30 days

-89.8%

Last 90 days

-90.7%

Trailing 12 Months

-87.5%

How does ACOR drawdown profile look like?

ACOR Financial Health

Current Ratio

0.33

ACOR Investor Care

Shares Dilution (1Y)

2.07%

Diluted EPS (TTM)

-203.7

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023118.3M116.9M111.1M117.6M
2022122.7M122.0M124.1M118.6M
2021153.7M151.9M130.3M129.1M
2020176.4M159.9M165.3M153.0M
2019409.4M306.2M211.1M192.4M
2018575.1M588.9M590.7M471.4M
2017523.1M535.1M540.5M588.3M
2016508.7M522.5M509.9M519.6M
2015420.8M437.4M479.6M492.7M
2014345.1M355.2M376.2M401.5M
2013306.4M317.8M325.3M336.4M
2012302.2M312.6M297.0M305.8M
2011235.1M256.9M286.3M292.2M
201057.3M86.0M135.2M191.1M
2009053.8M54.2M54.7M
200800053.4M

Tracking the Latest Insider Buys and Sells of Acorda Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 17, 2023
cohen ron
bought
6,500
0.65
10,000
president and ceo
Mar 16, 2023
cohen ron
bought
6,093
0.6
10,156
president and ceo
Sep 03, 2022
clem kerry m
sold (taxes)
-601
0.398
-1,511
chief commercial officer
Sep 03, 2022
sabella lauren m
sold (taxes)
-601
0.398
-1,511
chief operating officer
Mar 17, 2022
cohen ron
sold
-3,894
1.7014
-2,289
president and ceo
Sep 03, 2021
morales robert
sold (taxes)
-1,962
4.38
-448
interim pao & pfo
Sep 03, 2021
sabella lauren m
sold (taxes)
-6,618
4.38
-1,511
chief commercial officer
Sep 03, 2021
cohen ron
sold (taxes)
-17,257
4.38
-3,940
president and ceo
Mar 03, 2021
blank burkhard
acquired
-
-
11,125
cmo and head of r&d
Mar 03, 2021
sabella lauren m
acquired
-
-
11,125
chief commercial officer

1–10 of 49

Which funds bought or sold ACOR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
added
0.69
2,190
163,093
-%
Feb 14, 2024
Royal Bank of Canada
unchanged
-
-
-
-%
Feb 14, 2024
Saltoro Capital, LP
unchanged
-
-146,250
731,250
1.95%
Feb 14, 2024
Davidson Kempner Capital Management LP
unchanged
-
51,285
801,257
0.02%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
new
-
754
754
-%
Feb 14, 2024
DEUTSCHE BANK AG\
sold off
-100
-25,483
-
-%
Feb 13, 2024
BlackRock Inc.
reduced
-2.21
-1,585
100,021
-%
Feb 13, 2024
ACADIAN ASSET MANAGEMENT LLC
unchanged
-
-
489,000
-%
Feb 13, 2024
MORGAN STANLEY
unchanged
-
116
17,745
-%
Feb 13, 2024
FIRST MANHATTAN CO. LLC.
unchanged
-
1.00
45.00
-%

1–10 of 24

Are Funds Buying or Selling ACOR?

Are funds buying ACOR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACOR
No. of Funds

Unveiling Acorda Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 10, 2023
davidson kempner capital management lp
0.13%
31,311
SC 13D/A
Mar 10, 2023
davidson kempner capital management lp
0.21%
51,189
SC 13D/A
Feb 14, 2023
canyon capital advisors llc
0.00%
0
SC 13G/A
Feb 13, 2023
renaissance technologies llc
3.57%
868,892
SC 13G/A
Jan 23, 2023
davidson kempner capital management lp
0.24%
59,129
SC 13D/A
Jun 10, 2022
soros fund management llc
0%
0
SC 13G
Jun 10, 2022
davidson kempner capital management lp
0.28%
68,229
SC 13D
Feb 14, 2022
ubs oconnor llc
0%
0
SC 13G/A
Feb 14, 2022
point72 asset management, l.p.
4.1%
464,276
SC 13G/A
Feb 14, 2022
canyon capital advisors llc
5.79%
649,031
SC 13G/A

Recent SEC filings of Acorda Therapeutics Inc

View All Filings
Date Filed Form Type Document
Apr 04, 2024
8-K
Current Report
Apr 02, 2024
8-K
Current Report
Apr 01, 2024
10-K
Annual Report
Mar 13, 2024
8-K
Current Report
Jan 11, 2024
8-K
Current Report

Peers (Alternatives to Acorda Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
355.4B
85.2B
-8.42% -11.18%
10.11
4.17
6.46% 95.94%
318.5B
60.1B
2.93% 8.79%
872.48
5.3
1.40% -97.49%
146.0B
46.5B
-8.36% -37.64%
-105.17
3.14
42.59% -114.62%
143.2B
28.2B
-3.17% 6.28%
21.32
5.08
7.09% 2.52%
84.8B
27.1B
-10.35% -18.24%
14.97
3.13
-0.60% 23.36%
14.9B
15.8B
-2.56% 43.63%
-25.86
0.94
6.17% 76.47%
MID-CAP
4.1B
4.7B
-2.22% -17.04%
-323.64
0.88
4.58% 90.97%
4.1B
1.7B
-15.21% -18.31%
11.46
2.45
49.61% 324.78%
3.2B
8.8B
-5.60% 16.18%
-5.41
0.37
7.79% -163.11%
1.9B
644.4M
-8.96% -5.30%
13.86
2.96
29.14% 50.51%
SMALL-CAP
1.4B
743.2M
9.58% -25.31%
-4.02
1.91
24.65% 80.36%
22.9M
70.0M
-16.39% -47.35%
-2.23
0.38
-19.54% -109.18%
19.0M
-
-4.27% 58.66%
-1.03
0.22
2882.68% -138.52%
1.1M
19.6M
-49.30% -95.63%
-0.07
0.05
80.00% 43.08%
819.8K
117.6M
-89.85% -87.50%
0
0.01
-0.79% -283.60%

Acorda Therapeutics Inc News

Latest updates
Defense World22 hours ago
Yahoo Finance03 Apr 202407:00 am
Seeking Alpha03 Apr 202407:00 am
InvestorPlace02 Apr 202407:00 am

Acorda Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue37.1%37,985,00027,715,00029,675,00022,258,00031,470,00033,511,00031,051,00022,534,00036,967,50031,456,00031,785,00028,862,00038,160,00053,090,00033,618,00028,099,00050,496,00047,722,00050,053,00044,137,00069,152,000
Costs and Expenses843.7%285,310,00030,234,00033,307,00033,734,00031,203,00038,500,00044,966,00039,237,00048,526,50054,465,00047,474,00057,643,000116,554,50037,053,00043,168,00034,268,00036,010,500307,072,00073,442,00087,516,000118,452,500
  S&GA Expenses-4.1%22,206,50023,152,00021,825,00022,514,00026,254,00022,997,00030,067,00026,938,00028,440,00029,623,00032,368,00033,968,00032,876,50039,935,00038,656,00041,108,00041,224,00048,702,00050,195,00052,725,00036,819,000
  R&D Expenses-16.4%1,009,0001,207,0001,550,0001,386,0001,202,0001,383,0001,525,0001,694,0001,366,0001,931,0002,374,0004,749,0004,323,0005,729,0005,255,0007,705,0009,023,00016,073,00018,959,00016,028,00027,058,000
EBITDA Margin-597.2%-1.980.400.350.280.23-0.10-0.25-0.27-0.35-0.84-0.45----------
Interest Expenses2.8%8,205,0007,984,0007,773,0007,571,0007,699,0007,465,0007,474,0007,562,0007,338,0007,167,0007,705,0007,825,0007,764,0007,760,0007,484,0007,566,0005,570,0004,500,0005,378,0006,424,0005,271,000
Income Taxes-3362.5%-38,088,000-1,100,000-2,000,000-2,000,0002,419,0001,400,00026,600,000300,0001,680,000-3,100,000-500,000-3,200,000-3,092,0001,465,000571,000-6,998,000-791,50020,000214,000-715,000-63,081,500
Earnings Before Taxes-2473.4%-255,870,000-9,943,000-11,346,000-18,862,00021,574,000-12,438,000-20,119,000-24,264,000-18,899,500-30,176,000-23,395,000-36,603,000-86,159,0008,812,000-16,850,000-13,470,00064,862,000-263,518,000-27,272,000-48,320,000-53,465,500
EBT Margin-1405.2%-2.52-0.17-0.18-0.25-0.30-0.61-0.77-0.79-0.85-1.35-0.90----------
Net Income-2350.1%-217,761,000-8,888,000-9,381,000-16,824,00019,142,000-13,854,000-46,682,000-24,522,000-20,567,500-27,071,000-22,864,000-33,451,000-83,048,0007,347,000-17,421,000-6,472,00065,660,000-263,535,000-27,486,000-47,605,0009,595,000
Net Income Margin-1397.4%-2.15-0.14-0.18-0.49-0.56-0.85-0.97-0.77-0.81-1.28-0.87----------
Free Cashflow-Infinity%-3,062,000--11,556,000-7,018,0009,066,000-1,866,000-14,584,000-13,676,0003,239,000-9,012,000-8,824,000-26,916,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-70.4%1093663653753963934064244554664915846337107287548008801,1971,2341,300
  Current Assets1.4%75.0074.0065.0068.0082.0072.0077.0080.0010297.00113190221152158168201314358418528
    Cash Equivalents-7.7%30.0032.0025.0030.0038.0021.0023.0032.0046.0036.0046.0011771.0058.0041.0032.0062.00120148197294
  Inventory-10.0%16.0018.0015.0013.0013.0015.0015.0015.0019.0021.0025.0027.0029.0030.0033.0026.0025.0027.0028.0031.0029.00
  Net PPE-5.9%2.002.002.002.003.003.003.004.004.005.006.006.007.0013914214314313111383.0061.00
  Goodwill-------------------281280282
  Current Liabilities392.0%22846.0030.0035.0038.0042.0041.0046.0054.0068.0068.0013313713913871.0086.0092.0094.0097.00140
  Long Term Debt-100.0%-181176171167163159155151147144141138135132195193326324321319
    LT Debt, Non Current-100.0%-181176171167163159155151147144141138135132195193326324321319
Shareholder's Equity167.9%15859.0068.0077.0094.0076.0088.00128151164190206238314291307311281545567612
  Retained Earnings-22.4%-1,189-971-962-953-936-955-941-894-870-849-822-799-766-683-690-673-666-732-468-441-393
  Additional Paid-In Capital0.0%1,0301,0301,0301,0301,0301,0301,0291,0241,0231,0161,0161,0081,0081,0009839819791,0151,0121,0091,005
Shares Outstanding0%1.001.001.001.001.001.001.001.001.001.000.000.00---------
Float---16.00---11.00---52.00---35.00---363--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-139.7%-3,0187,608-11,556-7,0189,066-1,839-14,514-13,6373,240-9,012-8,688-26,8881,448-2,905-20,770-38,779-11,429-24,351-14,891-77,496-12,338
  Share Based Compensation-2.1%13814112871.001733644714854808549547071,5882,4802,0561,9762,7563,2934,5343,6675,006
Cashflow From Investing-Infinity%-44.00---123-150-70.00-39.00-1.00--13673,9155,01920,14823,15011,04355,998-3,276-35,106-18,121-14,829
Cashflow From Financing------------69,000-655--90.00--1,578-59,869--39.00-64262.00
  Buy Backs-------------------39.0052.00157

ACOR Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues:  
Total net revenues$ 117,633$ 118,566
Costs and expenses:  
Cost of sales15,28330,332
Research and development5,1525,804
Selling, general and administrative89,698106,256
Intangible asset impairment251,322 
Amortization of intangible assets30,76430,764
Changes in fair value of derivative liability (37)
Changes in fair value of acquired contingent consideration(9,634)(6,659)
Other operating income (12,554)
Total operating expenses382,585153,906
Operating loss(264,952)(35,340)
Other income (expense), net:  
Interest and amortization of debt discount expense(31,533)(30,200)
Interest income5301,909
Realized Gain (Loss) on FX Currency(288)(8)
Gain on extinguishment of debt 27,142
Gain on disposal of property and equipment171 
Other income (expense)511,250
Total other income (expense), net(31,069)93
Loss before taxes(296,021)(35,247)
Benefit from (Provision for) income taxes43,167(30,669)
Net loss$ (252,854)$ (65,916)
Net loss per share—basic$ (203.57)$ (65.23)
Net loss per share—diluted$ (203.57)$ (65.23)
Weighted average common shares outstanding used in computing net loss per share—basic1,2421,011
Weighted average common shares outstanding used in computing net loss per share—diluted1,2421,011
Net Product Revenues  
Revenues:  
Total net revenues$ 102,421$ 103,845
Royalty Revenues  
Revenues:  
Total net revenues15,11314,221
License Revenue  
Revenues:  
Total net revenues$ 99$ 500

ACOR Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 29,979$ 37,536
Restricted cash3816,884
Trade accounts receivable, net of allowances of $962 and $842, as of December 31, 2023 and 2022, respectively17,29813,866
Prepaid expenses5,2114,312
Inventory, net16,15512,752
Other current assets5,7706,765
Total current assets74,79482,115
Property and equipment, net of accumulated depreciation2,0792,603
Intangible assets, net of accumulated amortization and impairment22,987305,087
Right of use asset, net of accumulated amortization4,2215,287
Restricted cash255255
Other assets4,189248
Total assets108,525395,595
Current liabilities:  
Accounts payable13,3739,809
Accrued expenses and other current liabilities24,31023,680
Convertible senior notes186,1430
Current portion of lease liability1,5881,545
Current portion of acquired contingent consideration2,1322,532
Deferred revenue227384
Total current liabilities227,77337,950
Convertible senior notes0167,031
Non-current portion of acquired contingent consideration27,36838,668
Deferred tax liability044,202
Non-current portion of lease liability3,1664,341
Other non-current liabilities8,1749,781
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value per share. Authorized 1,000,000 shares at December 31, 2023 and 2022; no shares issued as of December 31, 2023 and 2022
Common stock, $0.001 par value per share. Authorized 3,083,333 shares at December 31, 2023 and 2022; issued 1,242,376 and 1,242,376 shares, including those held in treasury, as of December 31, 2023 and 2022, respectively124
Treasury stock at cost (278 shares at December 31, 2023 and December 31, 2022)(638)(638)
Additional paid-in capital1,030,3831,029,881
Accumulated deficit(1,189,127)(936,273)
Accumulated other comprehensive loss1,425628
Total stockholders' equity (deficit)(157,956)93,622
Total liabilities and stockholders’ equity$ 108,525$ 395,595
ACOR
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.
 CEO
 WEBSITEacorda.com
 INDUSTRYPharmaceuticals
 EMPLOYEES111

Acorda Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Acorda Therapeutics Inc? What does ACOR stand for in stocks?

ACOR is the stock ticker symbol of Acorda Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acorda Therapeutics Inc (ACOR)?

As of Thu Apr 11 2024, market cap of Acorda Therapeutics Inc is 819.78 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACOR stock?

You can check ACOR's fair value in chart for subscribers.

What is the fair value of ACOR stock?

You can check ACOR's fair value in chart for subscribers. The fair value of Acorda Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Acorda Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACOR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Acorda Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ACOR is over valued or under valued. Whether Acorda Therapeutics Inc is cheap or expensive depends on the assumptions which impact Acorda Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACOR.

What is Acorda Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 11 2024, ACOR's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACOR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Acorda Therapeutics Inc's stock?

In the past 10 years, Acorda Therapeutics Inc has provided -0.555 (multiply by 100 for percentage) rate of return.